Duricef (cefadroxil) is a first-generation cephalosporin antibiotic indicated for the treatment of a wide range of bacterial infections. It functions by inhibiting bacterial cell wall synthesis, leading to bactericidal activity against susceptible organisms. This oral formulation offers convenient dosing and reliable bioavailability, making it a practical choice for both outpatient and follow-up care. Healthcare providers value its spectrum of coverage for common pathogens in skin, urinary tract, and respiratory infections.

Features

• Active ingredient: cefadroxil (monohydrate)
• Available in 500 mg and 1 g capsules, and oral suspension
• Bactericidal activity against Gram-positive and some Gram-negative bacteria
• Stable in gastric acid, allowing for consistent absorption
• Can be taken with or without food
• Typically dosed once or twice daily depending on indication

Benefits

• Effectively treats common bacterial infections such as streptococcal pharyngitis, skin and soft tissue infections, and urinary tract infections
• Convenient once- or twice-daily dosing supports patient adherence
• Well-tolerated profile with a lower incidence of severe adverse effects compared to some broader-spectrum alternatives
• Suitable for both adult and pediatric populations (with weight-based dosing)
• Cost-effective option within the cephalosporin class
• Demonstrated efficacy in eradicating susceptible pathogens with a complete course

Common use

Duricef is commonly prescribed for bacterial infections caused by susceptible strains of streptococci, staphylococci (including penicillinase-producing strains), E. coli, Proteus mirabilis, and Klebsiella species. Typical indications include pharyngitis, tonsillitis, skin and skin structure infections, and uncomplicated urinary tract infections. It may also be used as follow-up therapy after initial parenteral antibiotic treatment.

Dosage and direction

The dosage of Duricef varies based on the infection type, severity, and patient factors such as renal function. For most infections in adults, the typical dose is 1–2 g per day, administered either once daily or in divided doses every 12 hours. For streptococcal pharyngitis, a once-daily regimen is often sufficient. Pediatric dosing is weight-based, usually 30 mg/kg/day in divided doses. Dosage adjustment is necessary in patients with renal impairment (creatinine clearance <50 mL/min). Tablets and capsules should be swallowed whole; the oral suspension must be shaken well before each use.

Precautions

Use with caution in patients with a history of gastrointestinal disease, particularly colitis. Renal function should be assessed before and during prolonged therapy. As with all antibiotics, Duricef may cause overgrowth of nonsusceptible organisms, including fungi. Patients should be advised to complete the full prescribed course even if symptoms improve earlier. Use during pregnancy only if clearly needed; it is excreted in breast milk.

Contraindications

Duricef is contraindicated in patients with known hypersensitivity to cefadroxil or other cephalosporin antibiotics. Cross-sensitivity with penicillins may occur; caution is advised in patients with penicillin allergy. Should not be administered to patients with a history of severe allergic reactions to beta-lactam antibiotics.

Possible side effect

Common side effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal pain. Less frequently, patients may experience headache, dizziness, or fatigue. Allergic reactions such as rash, urticaria, and pruritus can occur. Rare but serious side effects include pseudomembranous colitis, Stevens-Johnson syndrome, and hematologic changes such as neutropenia or elevated liver enzymes. Patients should seek medical attention if severe diarrhea, bloody stools, or signs of hypersensitivity develop.

Drug interaction

Probenecid may inhibit renal excretion of cefadroxil, increasing serum levels. Concurrent use with other nephrotoxic agents (e.g., aminoglycosides, loop diuretics) may enhance renal toxicity. Duricef may potentiate the effects of oral anticoagulants; monitor prothrombin time accordingly. False-positive reactions for glucose in the urine may occur with certain reduction-based tests (e.g., Benedict’s solution).

Missed dose

If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next dose, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose is not recommended.

Overdose

Symptoms of overdose may include nausea, vomiting, epigastric distress, and diarrhea. In cases of significant overdose, hemodialysis may aid in removal of the drug. Treatment is supportive and symptomatic; no specific antidote exists.

Storage

Store capsules and tablets at room temperature (15–30°C) in a tightly closed container. Protect from light and moisture. reconstituted oral suspension should be stored in the refrigerator and discarded after 14 days.

Disclaimer

This information is intended for healthcare professionals and should not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized recommendations. Dosage and suitability depend on individual patient factors.

Reviews

Clinical studies and post-marketing surveillance indicate that Duricef is generally well-tolerated and effective for approved indications. Healthcare providers report good patient compliance due to its convenient dosing. Some reviews note the need for culture and sensitivity testing to ensure appropriate use given rising antibiotic resistance.